News Release

Translation

April 26, 2018
JCR Pharmaceuticals Co., Ltd.

Notice on Change of Representative Directors

JCR Pharmaceuticals Co., Ltd. (TSE 4552: Chairman and President Shin Ashida, "JCR") announced that at the Board of Directors meeting held today, it has decided on the following changes in the Representative Directors .
Please note that the change of Representative Directors will be subject to approval at the Ordinary General Meeting of Shareholders and the Board of Directors meeting both scheduled for June , 2018.

Change of Representative Directors

(1) New Representative Director (effective: June, 2018)
Hiroshi Yoshimoto (current position: Senior Managing Director)

Career summary of the new Representative Director	
Name	Hiroshi Yoshimoto
Date of Birth	November 27, 1951
Ownership of shares	5,333 shares
Career	Apr. 1972 Taito Pfizer Co., Ltd. (currently Pfizer Japan Inc.) Dec. 1999 Plant Manager, Basic Production Plant, Nagoya Plant of the same Aug. 2003 Executive Officer, Pharmaceutical Bulk Manufacturing, Nagoya Plant of the same Mar. 2011 JCR Pharmaceuticals Co., Ltd. May 2011 General Manager, Production Division (current) Jul. 2011 Corporate Officer Jun. 2012 Director on the Board Jul. 2014 Managing Director Jun. 2016 Senior Managing Director (current)

(2) Retiring Representative Director (effective June, 2018)
Katsuya Nishino (current position: Executive Vice President and Assistant to the President)
※Mr. Nishino will be appointed "Senior Officer" at JCR's Ordinary General Meeting of Shareholders as scheduled on June, 2018 and will hold concurrent position as President and Representative Director of JCR USA, Inc.

[About JCR Pharmaceuticals]

JCR is a specialty pharma engaged in the research, development, manufacture and marketing of biopharmaceuticals and regenerative medicine with a focus on rare diseases. Its philosophy, “Contributing towards people’s healthcare through pharmaceutical products” drives JCR to create innovative pharmaceutical products as value-added treatment options for the under-served patient community.

[Cautionary Statement Regarding Forward-Looking Statements]

This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as “believe,” “estimate,” “anticipate,” “intend,” “plan,” “will,” “would,” “target” and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors’ pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights , an adverse court decision in a significant lawsuit and regulatory actions.

This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue.

Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.

Investors & Media:
JCR Pharmaceuticals Co., Ltd.
Corporate Communications
ir-info@jcrpharm.co.jp

END

###